

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SinoMab BioScience Limited**

**中國抗體製藥有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock code: 3681)**

**VOLUNTARY ANNOUNCEMENT  
IND APPLICATION FOR SM17 ACCEPTED BY NMPA CDE**

Reference is made to the announcements of SinoMab BioScience Limited (中國抗體製藥有限公司) (the “**Company**”, together with its subsidiaries, the “**Group**”) on 16 February 2022, 14 March 2022, 15 June 2022 and 22 May 2023 in relation to the latest research and development progress of one of the Group’s key products, SM17.

The board of directors (the “**Board**”) of the Company is pleased to announce that on 9 June 2023, an Investigational New Drug application (“**IND**”, for atopic dermatitis (“**AD**”)) for SM17 has been filed with and accepted by the Center for Drug Evaluation (the “**CDE**”) of the National Medical Products Administration of China (the “**NMPA**”). The Company plans to initiate a Phase I clinical study in China upon approval of the present IND. The present IND submission, once granted, will enable the Company to conduct comprehensive clinical development program in China which leads to indication for treatment of AD.

SM17 is a humanized, IgG4-k monoclonal antibody targeting IL-17RB. SM17 could suppress Th2 immune responses by binding to IL-17RB on Type 2 Innate Lymphoid cells (ILC2s) and Type 2 helper T (Th2) cells, blocking a cascade of responses induced by interleukin-25 (IL-25). IL-25 is a critical cytokine classified as “alarmin”, which has shown to be implicated in the pathogenesis of autoimmune and inflammatory skin diseases, such as AD. Patients with AD also have an increasing all-cause mortality rate and disease-specific mortality rate in the following diseases, which includes infections, respiratory diseases, gastrointestinal diseases and oncologic diseases. Current approved therapies for AD, including biologics, can significantly improve eczema area and severity index and patient’s quality of life. However, there is still an unmet medical need for patients showing

irresponsiveness to those approved therapies. We expect that targeting upstream mediators of the Th2 inflammatory cascade, such as IL-17RB, will have a broad effect on skin inflammation. We believe in the huge potential of SM17 to satisfy unmet medical needs in AD treatment.

By Order of the Board  
**SinoMab BioScience Limited**  
**Dr. Shui On LEUNG**

*Executive Director, Chairman and Chief Executive Officer*

Hong Kong, 12 June 2023

*As at the date of this announcement, the executive director of the Company is Dr. Shui On LEUNG, the non-executive directors of the Company are Dr. Haigang CHEN, Mr. Xun DONG, Ms. Wenyi LIU, Ms. Jie LIU, Mr. Lei SHI, and the independent non-executive directors of the Company are Mr. George William Hunter CAUTHERLEY, Mr. Ping Cho Terence HON, Dr. Chi Ming LEE and Mr. Dylan Carlo TINKER.*